 | Up a level |
Ribi, Karin; Luo, Weixiu; Colleoni, Marco; Karlsson, Per; Chirgwin, Jacquie; Aebi, Stefan; Jerusalem, Guy; Neven, Patrick; Di Lauro, Vincenzo; Gomez, Henry L; Ruhstaller, Thomas; Abdi, Ehtesham; Biganzoli, Laura; Müller, Bettina; Barbeaux, Annelore; Graas, Marie-Pascale; Rabaglio, Manuela; Francis, Prudence A; Foukakis, Theodoros; Pagani, Olivia; ... (2020). Correction: Quality of life under extended continuous versus intermittent adjuvant letrozole in lymph node-positive, early breast cancer patients: the SOLE randomised phase 3 trial. British journal of cancer, 122(7), p. 1119. Nature Publishing Group 10.1038/s41416-019-0709-x
Ribi, Karin; Luo, Weixiu; Colleoni, Marco; Karlsson, Per; Chirgwin, Jacquie; Aebi, Stefan; Jerusalem, Guy; Neven, Patrick; Di Lauro, Vincenzo; Gomez, Henry L; Ruhstaller, Thomas; Abdi, Ehtesham; Biganzoli, Laura; Müller, Bettina; Barbeaux, Annelore; Graas, Marie-Pascale; Rabaglio, Manuela; Francis, Prudence A; Foukakis, Theodoros; Pagani, Olivia; ... (2019). Quality of life under extended continuous versus intermittent adjuvant letrozole in lymph node-positive, early breast cancer patients: the SOLE randomised phase 3 trial. British journal of cancer, 120(10), pp. 959-967. Springer Nature 10.1038/s41416-019-0435-4
